The assay functions as a diagnostic tool to identify PD-L1 levels in patients considering treatment with Roche’s cancer drug Tecentriq. PD-L1 is a protein that makes individuals more receptive to immunotherapy treatments.
Better insight into a patient’s PD-L1 levels can indicate the potential survival benefits associated with using Tecentriq as a treatment.
More articles on supply chain:
EpiPen price hikes cost DOD millions
Kits for care: How global sourcing helped Northside Hospital boost patient comfort
FDA approves Medtronic’s larger aortic valve replacement system
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.